Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Primary purpose: not given (lowers risk) · Design
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ascendingsafety tolerabilitydosesplacebothe safety
  Phrases that lowered it: healthymale volunteerseffect ofthe effectinvestigate the
• Trials the sponsor started in the prior 2 years: 296 (raises risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Sponsor's past trials: 537 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 72.9% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past termination rate: 6.9% (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 332 (lowers risk) · Drug's FDA history
• Maximum age: 45 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 40 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017 NCT00791752 · started 2008 · scored riskier than 13% of active trials completed
• Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses NCT00841048 · started 2009 · scored riskier than 12% of active trials completed
• Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers NCT01588626 · started 2012 · scored riskier than 3% of active trials completed
• Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687 NCT01217905 · started 2010 · scored riskier than 50% of active trials completed
• A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers NCT00741689 · started 2008 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.